“脑机接口”新突破!难治性癫痫患者迎来曙光

2022-03-17 宣武医院 网络

该例植入手术的顺利完成标志着由宣武医院作为牵头单位的 Epilcure™国家药品监督管理局注册临床试验的首例患者成功入组。

近日,宣武医院院长赵国光教授,神经外科单永治教授带领的神经外科立体定向与功能性脑疾病组团队成功为一名难治性癫痫患者(双侧颞叶癫痫)施行了闭环反应性神经刺激系统Epilcure™注册临床试验植入手术。手术过程顺利,术中刺激器各项指标均工作正常,术后重建显示电极位置精准,脑电信号清晰。该例植入手术的顺利完成标志着由宣武医院作为牵头单位的 Epilcure™国家药品监督管理局注册临床试验的首例患者成功入组。

患者为男性,入院后诊断为双侧颞叶癫痫,此类癫痫为开颅手术的相对禁忌症,在药物无法控制的情况下,传统治疗效果欠佳 。闭环反应性神经刺激系统为“脑机接口”在临床领域的重要应用,该技术通过将人工智能芯片植入颅骨,颅内电极植入脑内,昼夜无间断监测脑电节律,一旦预测到即将发生的癫痫,即启动外源性干扰节律,直接阻断致痫灶内的癫痫形成,精准的控制环路的活动。这一新技术,为多灶或功能区的癫痫患者带来了福音,国外产品于2013年获得美国FDA认证通过,却作为“卡脖子”技术对我国进行长期技术封锁与限制。该系统的植入,意味着经过国内临床与基础研究团队艰苦卓绝的努力与攻关,具备自主知识产权的“脑机接口”高新技术产品已经走到了全方位临床使用前的最后一步。

患者影像评估

宣武医院作为国家神经疾病医学中心,在中心主任赵国光教授的带领下,在临床单位中较早就启动了“脑机接口”的研究。或许很多人还记得2014 年巴西世界杯的开幕式场景:一名因车祸造成完全性脊髓损伤、已经截瘫9年的患者在“重拾行走计划”的帮助下实现了站立、行走、并开出第一脚球。患者通过脑机接口技术,逐渐恢复下肢运动功能,可驱动外骨骼机器人行走。2018年2月6日,首都医科大学宣武医院院长赵国光教授与“重拾行走计划”发起人Miguel Nicolelis 教授开展合作,宣武医院成为亚洲首家加入到Walk again project(WAP)这一代表全球脑机接口技术最高水平项目的机构。基于该框架,中心组建了人工智能脑网络实验室、类脑智能临床转化研究中心、中美共建脑连接组学实验室、光遗传神经环路实验室等,全面开展脑机接口、脑电解码、人工智能及脑连接组学研究,推进脑科学向临床转化。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1725071, encodeId=5fc21e2507191, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Sat Apr 23 21:30:05 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725209, encodeId=2a2b1e2520905, content=<a href='/topic/show?id=58476021257' target=_blank style='color:#2F92EE;'>#曙光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60212, encryptionId=58476021257, topicName=曙光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=180c33737541, createdName=yangpeizhi, createdTime=Tue Nov 22 12:30:05 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009240, encodeId=34de2009240d7, content=<a href='/topic/show?id=1a35e15712e' target=_blank style='color:#2F92EE;'>#癫痫患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71571, encryptionId=1a35e15712e, topicName=癫痫患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 31 15:30:05 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528849, encodeId=c09415288491a, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Mar 18 23:30:05 CST 2022, time=2022-03-18, status=1, ipAttribution=)]
    2022-04-23 zxxiang
  2. [GetPortalCommentsPageByObjectIdResponse(id=1725071, encodeId=5fc21e2507191, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Sat Apr 23 21:30:05 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725209, encodeId=2a2b1e2520905, content=<a href='/topic/show?id=58476021257' target=_blank style='color:#2F92EE;'>#曙光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60212, encryptionId=58476021257, topicName=曙光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=180c33737541, createdName=yangpeizhi, createdTime=Tue Nov 22 12:30:05 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009240, encodeId=34de2009240d7, content=<a href='/topic/show?id=1a35e15712e' target=_blank style='color:#2F92EE;'>#癫痫患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71571, encryptionId=1a35e15712e, topicName=癫痫患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 31 15:30:05 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528849, encodeId=c09415288491a, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Mar 18 23:30:05 CST 2022, time=2022-03-18, status=1, ipAttribution=)]
    2022-11-22 yangpeizhi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1725071, encodeId=5fc21e2507191, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Sat Apr 23 21:30:05 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725209, encodeId=2a2b1e2520905, content=<a href='/topic/show?id=58476021257' target=_blank style='color:#2F92EE;'>#曙光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60212, encryptionId=58476021257, topicName=曙光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=180c33737541, createdName=yangpeizhi, createdTime=Tue Nov 22 12:30:05 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009240, encodeId=34de2009240d7, content=<a href='/topic/show?id=1a35e15712e' target=_blank style='color:#2F92EE;'>#癫痫患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71571, encryptionId=1a35e15712e, topicName=癫痫患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 31 15:30:05 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528849, encodeId=c09415288491a, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Mar 18 23:30:05 CST 2022, time=2022-03-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1725071, encodeId=5fc21e2507191, content=<a href='/topic/show?id=9ee758586bb' target=_blank style='color:#2F92EE;'>#新突破#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58586, encryptionId=9ee758586bb, topicName=新突破)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=792a33728807, createdName=zxxiang, createdTime=Sat Apr 23 21:30:05 CST 2022, time=2022-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725209, encodeId=2a2b1e2520905, content=<a href='/topic/show?id=58476021257' target=_blank style='color:#2F92EE;'>#曙光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60212, encryptionId=58476021257, topicName=曙光)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=180c33737541, createdName=yangpeizhi, createdTime=Tue Nov 22 12:30:05 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009240, encodeId=34de2009240d7, content=<a href='/topic/show?id=1a35e15712e' target=_blank style='color:#2F92EE;'>#癫痫患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71571, encryptionId=1a35e15712e, topicName=癫痫患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jan 31 15:30:05 CST 2023, time=2023-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528849, encodeId=c09415288491a, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Mar 18 23:30:05 CST 2022, time=2022-03-18, status=1, ipAttribution=)]
    2022-03-18 freve

相关资讯

5种脑叶癫痫病症状学定位总结,一文掌握!

癫痫是大脑神经元突发性超同步异常放电所致短暂的大脑功能失调的一种慢性脑部疾病。由于异常放电的神经元在大脑中的部位不同,而有多种临床表现,依据癫痫发作症状学进行病灶定位更是每一位神经科医生的必备技能。

JNNP:丘脑神经刺激改善特发性全身性癫痫发作控制

这个数字的五分之一大约是在美国,有100万癫痫患者被诊断为特发性全身性癫痫(IGE)。其中约10%–40%的患者从未通过药物获得足够的癫痫控制,

Neurology:结节性硬化(TSC)患儿早期MRI特征与继发癫痫、2岁前神经发育结局存在显著相关!

在患结节性硬化症(TSC)的婴儿中,早期脑MRI检测到的特征性TSC病变与临床癫痫的发展、出生后头两年的神经发育结果间存在显著的相关性。根据该研究结果,早期的脑MRI表现可以指导儿童TSC的临床治疗。

Epilepsia:丘脑功能连接可预测停用抗癫痫药后癫痫复发

该研究确定了有或无癫痫复发的患者在停用抗癫痫药时丘脑皮层功能连接的明显特征,显示出其在停用抗癫痫药后预测癫痫发作结局的潜力。

JAMA N:卒中后癫痫应该选用哪一种药物?

卒中是成人新发癫痫最常见的病因。

Neurology:癫痫儿童语言神经网络存在静息状态功能连接性(FC)差异,适应、补偿形式反映神经网络可塑性

近日,有学者对比了典型发育期儿童(TD)和癫痫儿童的语言静息状态功能连接性(RS fMRI;FC),发现基于疾病、癫痫灶位置和生长发育中的FC差异,表明FC以适应和补偿的形式反映了神经网络的可塑性。